Pharmacogenomics public workshop
Executive Summary
FDA public workshop to discuss a draft guidance on the co-development of pharmacogenomics tests with a drug or biologic is planned for April 11-13, 2005 in Bethesda, Md. The draft guidance is expected by the end of the year. The agency published a draft guidance on pharmacogenomics data submissions in November 2003 (1"The Pink Sheet" Nov. 10, 2003, p. 11)...
You may also be interested in...
FDA Genomics Guidance Paves Way For PKG Firms; Genaissance May Benefit
Genaissance Pharmaceuticals is developing a pharmacogenomics-based assay for predicting an individual occurrence of agranulocytosis associated with the antipsychotic clozapine (Novartis' Clozaril and generics)
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.